Mats Grahn

This profile gathers the share dealings of Mats Grahn across 2 companies, led by Immunovia AB and Immunovia. Over a trading history stretching from 26 September 2017 to 19 June 2019, the count stands at 3 filings.

Market trades split into 1 purchase (€322k) and 2 sales (€1.1M). Sales outweigh purchases by €799k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Since January 2019: no purchases and 1 sale on the market.

The latest filing, published on 20 June 2019, reports an open-market sale of €757k in Immunovia AB. The clock since the last published purchase (29 September 2017) now reads 3,327 days. Typically, a trade is published a median of 1 day after it takes place. The legal deadline for notifying a trade is three business days (MAR article 19). A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.